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The advent of endoscopic ultrasound-guided sampling procedures such as endoscopic ultra-
sound-guided fine-needle aspiration (EUS-FNA) and endobronchial ultrasound-guided trans-
bronchial needle aspiration (EBUS-TBNA) has lead to significant advances in the mediastinal
diagnosis and staging of lung cancer. These endoscopic techniques can be performed in the
outpatient setting under conscious sedation and local anesthesia, in contrast to the surgical
standard, mediastinoscopy (MS), which requires operating theatre time and general anes-
thesia. Proponents of mediastinoscopy have always emphasized the advantages of mediastino-
scopy, namely its sensitivity even with a low prevalence of mediastinal metastases and its low
false negative rate. Newer endoscopic techniques such as EBUS-TBNA are showing sensitivities
exceeding that of mediastinoscopy, even in the setting of an equally low prevalence of medi-
astinal metastases. However, endoscopic techniques have double the false negative rate of
mediastinoscopy. As the tracheobronchial route and esophageal route provide almost
complete access to mediastinal lymph nodes, these endoscopic techniques are complementary
rather than competing. When used in combination, it is possible mediastinoscopy may be
superseded. The challenge however, is how best to select the appropriate endoscopic proce-
dures to accurately stage lung cancer in the most cost-effective manner.
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worldandalso the leadingcauseof cancermortality.1 Surgery
offers the best chance of cure for non-small cell lung cancer,
which accounts formore than 80%of lung cancers. The 5-year
survival rate is about 45%after surgical resection for clinically
resectable disease.2 In the absence of extrathoracic metas-
tases, mediastinal lymph nodes are the commonest site of
metastases and this generally precludes surgical resection.
With ipsilateral mediastinal lymph node metastases, the
5-year survival falls to a dismal 23%.2 Therefore, in the
absence of distant metastases, mediastinal lymph node
involvement is the most important prognostic factor that is
critical to determining appropriate therapy.
Non-invasive mediastinal staging
The most commonly used modality for mediastinal staging
is CT scanning of the chest and the criterion used is
enlargement of the lymph node to 1 cm on its short axis.
The major limitation of using the CT criteria is not only its
poor sensitivity, but also its poor specificity. In a meta-
analysis of 5111 patients, the pooled sensitivity and speci-
ficity were 51% and 85% respectively.3 In fact, in one of the
included studies, up to 40% of lymph nodes deemed
malignant by CT criteria were actually benign.4 Functional
imaging with 18F-fluoro-2-deoxy-D-glucose has a higher
sensitivity than CT, but again, specificity remains poor.
Thus, when there are abnormal findings with the non-
invasive imaging modalities for mediastinal staging, tissue
confirmation is usually recommended.3,5
Surgical mediastinal staging
The diagnostic standard for tissue diagnosis in the medias-
tinal staging of lung cancer is mediastinoscopy, which
involves passing a rigid mediastinoscope into the medias-
tinum. This surgical technique has a reported morbidity and
mortality rate of 2% and 0.08% respectively.6 Excision biopsy
of lymph nodes lateral to the trachea (station 2 and 4) and
anterior subcarinal lymph nodes (station 7) can be per-
formed with this technique through dissection via a supra-
sternal incision while biopsy of subaortic (station 5) and
para-aortic (station 6) lymph nodes usually requires another
point of entry via a left anterior parasternal media-
stinotomy. Lymph nodes posterior to the carina and those in
the inferior mediastinum are however, beyond access of the
mediastinoscope. The availability of videomediastinoscopy
(VMS) allows better visualization and more extensive lymph
node sampling with a lower incidence of recurrent laryngeal
nerve damage and post-operative bleeding.7 VMS also gives
improved sensitivities (90%) and lower false negative rates
(7%) as compared to conventional mediastinoscopy (80% and10%),8 but both surgical procedures require operating
theatre time and general anesthesia.
Endoscopic mediastinal staging
Transbronchial needle aspiration (TBNA)
Transbronchial needle aspiration on the other hand, allows
sampling of mediastinal lymph nodes lying adjacent to the
tracheobronchial tree during bronchoscopy, which may be
done under local anesthesia as an outpatient procedure.
TBNA does not require expensive specialized ultrasound
equipment, is safe, and can be done as part of the initial
diagnostic bronchoscopy.10e12 However, its diagnostic
accuracy is highly variable as this is a blind technique that is
operator dependent. The sensitivity depends critically on
the prevalence of mediastinal lymph node metastases and
varies from 39% with a prevalence of mediastinal metastases
of 34%, to 78%with aprevalence ofmediastinalmetastases of
81%.9 It also has a high false negative rate that approaches
30%.8 Therefore, its limitations have precluded its use where
accurate mediastinal staging is required.
Endoscopic ultrasound-guided fine-needle
aspiration (EUS-FNA)
With a curved linear array ultrasound transducer, endoscopic
ultrasound-guidedfine-needle aspiration (EUS-FNA), permits
real-time ultrasound-guided needle sampling of lymph node
stations adjacent to the esophagus and therefore has
a higher sensitivity and accuracy as compared to TBNA. The
esophageal route allows access to left-sided mediastinal
(station 4L and 5) and subcarinal (station 7) lymph nodes. It
also allows access to lymphnodes in the inferiormediastinum
such as the lower paraesophageal (station 8) and the
pulmonary ligament (station 9) lymph nodes that are beyond
the reach of themediastinoscope and tracheobronchial tree,
but these lymph nodes are not commonly involved in lung
cancer. Even the para-aortic lymph node (station 6) can be
sampled through the intervening aorta via the esophagus.13
The pooled sensitivity is about 84% but the false negative
rate is still high at 19%.8 However, its sensitivity drops to 24%
for right paratracheal lymph nodes where an air-filled
intervening trachea limits ultrasound access from the left-
sided esophagus.14
Endobronchial ultrasound-guided transbronchial
needle aspiration (EBUS-TBNA)
Endobronchial ultrasound-guided transbronchial needle
aspiration uses very similar equipment to EUS-FNA, with the
Figure 1 An algorithm for endoscopic diagnosis/staging of
lung cancer.
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tracheobronchial route to be employed for real-time
ultrasound-guided sampling of lymph nodes adjacent to the
trachea. These are the mediastinal lymph nodes that are
commonly involved in lung cancer and include the para-
tracheal (station 2 and 4) and the subcarinal (station 7)
lymph nodes. A recent meta-analysis reported an impres-
sive pooled sensitivity of 93%.15
The advantage of both the ultrasound-guided endo-
scopic procedures is that they can be performed safely in
the outpatient setting under local anesthesia. When the
sensitivities of TBNA, EUS-FNA, and EBUS-FNA are
compared to mediastinoscopy in studies where the preva-
lence of mediastinal metastases is low, only the EBUS-TBNA
sensitivity exceeded that of mediastinoscopy (Table 1). In
a prospective study directly comparing EBUS-TBNA with
mediastinoscopy, the diagnostic yield of EBUS-TBNA also
surpassed that of mediastinoscopy.16
Limited accessibility of each endoscopic route and fine-
needle sampling error however contribute to a false nega-
tive rate which is double that of mediastinoscopy (EBUS-
TBNA and EUS-FNA has a false negative rate 20% and 19%
respectively, while mediastinoscopy has a false negative
rate of 10%).8 The deficiencies of the ultrasound-guided
endoscopic techniques seem to be minimized when these
procedures are used in combination. Wallace and
colleagues have demonstrated in a landmark study that
when EUS-FNA and EBUS-FNA were used in combination, the
sensitivity was 93% in a population with a mediastinal lymph
node prevalence of only 30.4%.17 More importantly, they
also reported a high negative predictive value of 97% and
suggested that this combination of ultrasound-guided
endoscopic procedures might substitute mediastinoscopy.
As the endobronchial and esophageal routes are comple-
mentary, virtually all lymph node stations within the
mediastinum may be accessed via these endoscopic routes.
Selecting a mediastinal staging method
While the result of combining two ultrasound-guided
endoscopic procedures may supercede that of the surgical
standard, a single appropriately selected endoscopic
procedure that is diagnostic for mediastinal metastases
may well be all that is required.18 In the event that both
endoscopic routes allow equal access to a suspicious lymph
node station, the issue becomes that of selecting the
procedure of choice. Though EUS-FNA may offer betterTable 1 Pooled sensitivities of MS, TBNA, EUS-FNA and
EBUS-FNA in studies with a prevalence of mediastinal
metastases below 40% based on data from reviews.8,9,15
Sensitivity Pooled
prevalence
of mediastinal
metastases
MS 76% 31%
TBNA 39% 34%
EUS-FNA 67% 36%
EBUS-FNA 81% 32%patient tolerance with less coughing as compared to EBUS-
TBNA, it has limited access to some of the lymph nodes that
are commonly involved in lung cancer. Finally, targeting the
mediastinum first in the setting of suspected lung cancer
may lead to simultaneous diagnosis and mediastinal staging
of non-small cell lung cancer with a single procedure.12,18,19
This may be more cost-effective than performing biopsy of
the lung mass, followed by mediastinal staging in
a sequential manner, especially when the likelihood of
mediastinal metastases is high (See Fig. 1).
In conclusion, given the availability of an armamen-
tarium of staging techniques for lung cancer, the challenge
is to select the most cost-effective way to accurately stage
the tumor. Due to the heterogeneity of patients and the
availability of techniques at different institutions, the
optimal approach to patient and procedure selection in
diagnosing and staging lung cancer remains to be defined,
but EBUS-TBNA is likely to be a key component.
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